cyrilzakka/clinical-trials huggingface dataset:
The Effect Of Multifidus And Transversus Abdominis Muscle Activation On Balance In Hemiplegic Patients

Patients with post-stroke hemiplegia may develop balance disorder and limitation in ambulation ability due to multiple mechanisms.

The effects of core muscles on maintaining normal posture, balance and ambulation ability are known. The positive effects of core stabilisation exercises on balance in hemiplegic patients have been shown in previous studies. In this study, we planned to investigate the effects of bilateral transversus abdominis and bilateral lumbar multifidus muscles on balance in patients with stroke-related hemiplegia.

Loss of function in the trunk muscles of stroke patients leads to both balance problems and excessive effort to maintain balance. While ambulation ability of some patients is completely lost due to stroke, in others, impaired balance and increased postural oscillation lead to fear of falling and increased risk of falling.

In previous studies, it has been shown that there is a significant relationship between static balance and duration of hospital stay and functional abilities after stroke. In another study, it was shown that the control ability of the trunk muscles in the early post-stroke period was a strong factor affecting general life activities in the first six months after stroke.

Trunk muscles are innervated by both hemispheres unlike the extremities. Therefore, unilateral stroke may impair the function of trunk muscles on both the contralateral and ipsilateral sides. Several studies have shown dysfunction of bilateral trunk flexor, extensor and rotator muscles in patients with unilateral stroke.

Many studies have proven that core stabilisation exercises are effective on both balance and gait function and general life activities in hemiplegic patients.

The aim of this cross-sectional study was to investigate the effect of ultrasound-guided bilateral transversus abdominis and bilateral lumbar multifidus muscle activations on balance in hemiplegic patients.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18-65 years
* Time after stroke must be at least 1 month
* Unilateral stroke
* Must be cognitively compatible in terms of cooperation
* Standing balance with/without support and/or sitting balance without support
* BMI\<30

Exclusion Criteria:

* Patients with a history of hemiplegia in the opposite half of the body
* Patients with extruded or sequestered lumbar hernia and/or history of lumbar operation
* Patients with a history of lumbar vertebral fracture
* Patients with traumatic brain injury
* Patients with neuromuscular muscle disease that may lead to muscle atrophy
* Patients with sensory defects
* Patients with cerebellar defects
* Patients with vestibular balance disorders (vertigo, etc.)
* Patients with Parkinson's disease
* Patients with balance problems due to visual impairment
* Patients with pre-stroke balance problems
Reporting Back Pesticide Results to Family Child Care Home Directors

Child Care Health Consultants will provide an integrated pest management (IPM) intervention for \~30 family child care home directors. The intervention will include an educational component, collecting carpet dust samples, reporting back the pesticides identified in the carpet, and 7-monthly consultations to identify ways to reduce their exposure to pesticides and lower their long term health risks.

The 12-month IPM intervention study conducted in family child care homes will include baseline and post-intervention interviews with the family child care home director, surveys, environmental assessments, and carpet dust samples. The intervention will include an IPM educational meeting where the director will receive an IPM Toolkit and toolbox, learn about the health risks related to repeated pesticide use. Six monthly consultations will be provided to focus on the goals set by the director to increase their IPM practices, reduce their use of pesticides, and lower the health risks for the children in their care, themselves and their staff. Three months after baseline, study staff will share the results of the pesticides detected in the dust samples to individual family child care home directors using Digital Exposure Report-Back Interface (DERBI). Interviews throughout the study period will be conducted with the family child care home directors to explore their reactions to and understanding of results, health effects, decisions made, intention to change pest management strategies, and/or share the results with families and their community.

Eligibility Criteria:
Inclusion Criteria: Director of a family child care home with 5 or more children in San Joaquin, Stanislaus, Tulare, or Fresno County in California. Plan to stay open for at least 12 months.

Exclusion Criteria: Does not read or speak English or Spanish.
Predictive Value of Human Microbiome and Serological Markers for Clinical Outcome of AIS With Active Cancer

Explore with active cancer patients with acute ischemic stroke in the human body characteristic microorganism disorder to clinical prognosis of the predictive value of the secondary objective: to observe with active cancer patients with acute ischemic stroke in the body of microorganisms and their serological indexes change law of exploration condition change related biomarkers of microscopic objects group based on the human body.

investigators recently found that changes in gut microbiota in patients with ischemic stroke are associated with the development of disease. However, there are few studies on the correlation between ischemic stroke with cancer and human microbiome and metabolites Whether the human microbiome and its metabolites are associated with the prognosis of such patients remains to be investigated. Therefore, this study hypothesized that structural changes in the human microbiome and its metabolites in patients with acute ischemic stroke with active cancer were associated with stroke severity and disease recovery Therefore, this topic proposed by collecting active follow-up cancer of acute ischemic stroke patients after admission and oral swabs Excrement and urine and blood samples, and based on the queue, follow-up analysis of the human microbiome dynamic change rule and the prognosis of patients with cancer of the acute ischemic stroke correlation, activity, further explore the secondary prevention of stroke management strategy based on the human microbiome.

Eligibility Criteria:
Inclusion Criteria:

* 1: It meets the diagnostic criteria for acute ischemic stroke

  2: Age ≥ 18 years

  3: The onset time is less than or equal to 2 weeks

  4: Diagnosis of cancer before stroke onset or during hospitalization and active cancer (failure to meet clinical criteria for cure, or discovery of recurrence or metastasis)

  5: Sign an informed consent form, provide relevant medical history information and provide biological specimens

Exclusion Criteria:

* 1: Previous history of disabling stroke (pre-onset mRS ≥2)

  2: Primary central nervous system tumor or hematologic system tumor

  3: The cancer meets the criteria for clinical cure and has not recurred or metastasized for more than 5 years

  4: Antibiotics, prebiotics/probiotics taken within 1 month

  5: Patients who cannot have stool specimens within 4 days of admission
Diabetes Lifestyle Assessment and Educational Tools

Aim: To evaluate a culturally-adapted method of lifestyle assessment, counseling, and education among Arab people with diabetes who have varying literacy skills using an interactive computerized tool and graphically-enhanced patient logs for dietary and physical activity.

The investigators hypothesize that this tool will: a) increase patients' knowledge and understanding of the role of lifestyle (diet and physical activity) in diabetes management; b) improve patients' engagement in monitoring dietary intake and physical activity; c) improve dietary and physical activity behaviors and self-blood glucose monitoring (SBGM) practices; d) improve glycemic control; and, e) improve the efficiency of lifestyle assessment, education and counseling while increasing patients' engagement in the process.

Aim: To evaluate a culturally-adapted method of lifestyle assessment, counseling, and education among Arab people with diabetes who have varying literacy skills using an interactive computerized tool and graphically-enhanced patient logs for dietary and physical activity. The investigators will evaluate the effectiveness of this method for: a) increasing patients' knowledge and understanding of the role of lifestyle (diet and physical activity) in diabetes management; b) improving patients' engagement in monitoring dietary intake and physical activity; c) improving dietary and physical activity behaviors and self-blood glucose monitoring (SBGM) practices; d) improving glycaemic control; and, e) improving the efficiency of lifestyle assessment, education and counseling while increasing patients' engagement in the process.

Eligibility Criteria:
Inclusion Criteria:

* 40-64 years old
* BMI 27-45 kg/m2
* Diagnosis of type 2 diabetes mellitus in medical record
* HbA1c 8.0%-11.5%

Exclusion Criteria:

* Short-acting insulin treatment
* Inadequate control of co-morbid conditions
* Factors that may limit adherence to interventions (e.g., any medical or physical condition that limits the ability to participate in physical activity or standard diets recommended for people with diabetes, pregnancy, uncontrolled psychiatric condition, significant cognitive impairment, blindness).
Pooled Analysis of Clinical Data From Six GSK Studies to Investigate the Efficacy of a Dentifrice Containing 67% Weight by Weight (w/w) Sodium Bicarbonate on Gingivitis and Plaque Accumulation

The aim of this analysis was to pool data from 6 GSK studies with similar clinical design to investigate the overall efficacy of a test dentifrice containing 67% w/w sodium bicarbonate in the treatment of gingivitis and plaque accumulation after 6, 12 and 24 weeks of twice-daily brushing at home relative to a negative control dentifrice.

The pooled analysis was planned and conducted after completion of all six independent studies.

This pooled analysis was performed on data collated from six GSK studies that provide efficacy data supporting the twice-daily use of a dentifrice containing 67% w/w sodium bicarbonate in the management of pre-existing gingivitis, and plaque accumulation. Six studies that were chosen for inclusion in the pooled analysis were single-center, examiner-blind, 2 to 3 treatments, parallel group, stratified and randomized clinical study. In all studies, participants entered the screening period during which eligibility for the study was determined. The participants included male and non-pregnant, non-lactating female subjects at least 18 years of age with pre-existing gingivitis as determined by an appropriately qualified clinical examiner. Participants meeting the inclusion criteria entered an acclimatization period in order to minimize any potential placebo response. Participants were randomized into treatments, parallel group, stratified and randomized clinical studies twice daily at home for 6, 12 and 24 weeks and participants returned to the site. Participants underwent a full OST examination and the recording of any Adverse Events (AEs). Participants then underwent Modified Gingival Index (MGI), Bleeding Index (BI), Gingival Severity Index (GSI) followed by dental plaque assessments.

Eligibility Criteria:
Inclusion Criteria:

* Clinical studies conducted by GSK CH, including access to study protocols, study reports, and access to individual information sources/ study data.
* Study design and subject inclusion criteria in agreement with guidelines to assess gingivitis efficacy such as inclusion of a pre-treatment full-mouth prophylaxis, Subject eligibility (\>20 bleeding sites and mild-moderate gingivitis at Screening);Comparable indices of gingivitis and plaque accumulation; a treatment for a 67% w/w sodium bicarbonate dentifrice; Repeat brushing for at least a period of 4 weeks or 4-6 weeks.

Exclusion Criteria: Not Applicable
A Comparative Study on the Efficacy of Different Stepping-down Therapy for Childhood Asthma

This study is a 24-week, randomized, parallel group comparative effectiveness study to evaluate the risk of stepping down therapy for patients with well-controlled asthma treated with combination Inhaled corticosteroids (ICS) and Leukotriene receptor antagonist（LTRA).

Asthma guidelines recommend stepping down therapy once asthma is controlled for at least 3 months. Leukotriene receptor antagonist（LTRA). For children with mild persistent asthma, ICS twice a day combined with LTRA can be used for treatment, but there is no consensus on how to reduce drugs in patients with asthma that is well controlled (reducing the dose of ICS or stopping montelukast). We propose a 24-week, randomized, parallel group comparative effectiveness study comparing three approaches in patients with asthma well-controlled for at least three months on combination ICS and LTRA: Halve the dose of ICS firstly and then stop ICS with montelukast only, stop montelukast firstly and then halve the dose of ICS, and halve the dose of ICS firstly and then stop montelukast. Our goal is to compare the rate of treatment failure and determine the optimal treatment strategy. Additional goals include assessing risk factors for step-down failure.

Eligibility Criteria:
Inclusion Criteria:

* age 4-14 years
* patients had mild to moderate persistent asthma. Patients have treated with low-dose inhaled corticosteroids (equivalent to Fluticasone propionate inhaled aerosol 250 ug/ day) combined with Leukotriene receptor antagonist (Montelulast) at least 6 months of and had no symptoms of asthma for nearly 3 months under well asthma control(Asthma Control Test (ACT) score more than or equal to 20).
* patients did not suffer from other acute or chronic diseases that may affect their growth and development

Exclusion Criteria:

* patients with severe persistent asthma or mild persistent asthma failed to be well controlled by low-dose ICS after starting treatment
* suffer from other diseases: Congenital heart disease, chronic infectious disease, protracted diarrhea, congenital airway disease, congenital vascular ring malformation, congenital immune deficiency, tracheal foreign body, bronchial lymph node tuberculosis and gastroesophageal reflux etc.
* patients with poor compliance stop medication or fail to take medication on time.
CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension

To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle glaucoma or ocular hypertension.

This is a prospective, multicenter, open label study, to evaluate the safety, tolerability and efficacy of OTX-TIC intracameral implant in subjects with primary open-angle glaucoma or ocular hypertension. The subjects will be followed for approximately 7 months (one-month washout and 6 months follow-up after injected of the OTX-TIC implant).

Eligibility Criteria:
Inclusion Criteria:

* Have a documented diagnosis of ocular hypertension or primary open-angle glaucoma
* Have IOP that is currently controlled as assessed by the Investigator
* Have open, normal appearing anterior chamber angles as determined by gonioscopy

Exclusion Criteria:

* Have closed angle glaucoma, narrow angle glaucoma, pseudoexfoliation syndrome, pseudoexfoliation glaucoma, pigment dispersion or pigmentary glaucoma, glaucoma diagnosis prior to 15 years of age, inflammatory, neovascular or other secondary
* Have a known or suspected allergy and/or hypersensitivity to a prostaglandin (i.e. travoprost), fluorescein or to any component of the study products
Evaluating Patient Comfort and Environmental Conditions in the Carecube Negative Pressure Isolation Chamber.1

This is a human non-significant risk (NSR) clinical study designed to objectively and participatively verify that the Carecube Negative Pressure Isolation Chamber is a safe and non-hostile environment for the patients that will be contained within the chamber during normal operations.

Device Information:

The Carecube Negative Pressure Isolation Chamber is a patient isolation unit (PIU) designed for the temporary isolation of patients within a hospital to prevent particulate (biological) cross-contamination between user and patient, while enclosing the contaminated patient from the external environment.

Study Description:

Participants will be tasked to stay within the Carecube Negative Pressure Isolation Chamber for a minimum of three consecutive time points (1 hour apart) illustrating a plateau level for all parameters, up to a maximum of 7 hours (readings will be taken at baseline and hourly thereafter).

The Carecube Negative Pressure Isolation Chamber will be set up indoors, in an emergency department and hospital floor environment. We will collect data and demonstrate that the Carecube Isolation chamber is a safe and non-hostile environment for the patients that will be contained within, during normal operations.

Each participant will be asked to come to a test center facility to complete and sign the informed consent and receive instruction to interact with the simulation. Subjects will be tasked to stay within the Carecube Isolation Chamber for at least 4 hours and have 3 consecutive timepoints illustrating a plateau level for all participants parameters.

Environmental data will be collected by physicians and nurses. Additionally, atmospheric Oxygen, Carbon Dioxide, humidity, and room temperature will be monitored and recorded. External to the room humidity and temperatures will also be recorded. The participant will be exposed to room temperature (° Fahrenheit) and humidity (RH%), ranging from 65°- 90° Fahrenheit and 30%-60% RH. Participants will also be asked to record on a questionnaire, in order to demonstrate that the Carecube Negative Pressure Isolation chamber is a safe and non-hostile environment for the patients that will be contained during normal operations.

Eligibility Criteria:
Inclusion Criteria:

Male, female, non-binary between the ages of 19-65 No existing medical condition that would impact the Subject from staying within the containment system for the specified time-period.

Patient is not pre-dispositioned for claustrophobia

Exclusion Criteria:

Subjects that have a pre-existing condition of claustrophobia Subjects that have a history of hypertension Subjects with a clinical diagnosis of generalized anxiety disorder (GAD) Subjects with a clinical diagnosis of major depressive disorder (MDD) Morbidly obese patients (BMI above 40) Subjects who are Women of Child Bearing Potential (WOCBP) who either are pregnant or suspect they are pregnant
Epicardial Mini-Maze Versus Catheter Ablation for the Management of Persistent Atrial Fibrillation

This study will assess the efficacy of catheter ablation versus the Wolf Mini-Maze surgical ablation for rhythm control in patients with persistent afib.

Higher success rates have been achieved after a single surgical ablation when compared to catheter ablation, however contiguous and transmural lesions are not always guaranteed.

Even though, catheter ablation is now being offered for symptomatic persistent AF, recurrence after the index procedure in such a persistent AF substrate is not unusual. Redo-catheter ablation is routinely offered for such patients; however long term success still remains low. Non-pulmonary vein triggers are often targeted in such redo-catheter ablation procedures; though this approach remains controversial. More recently, the Wolf Mini-Maze procedure has been utilized with promising results.

This study proposes to randomize a group of persistent AF patients to undergo either catheter ablation or the surgical mini-maze procedure with left atrial appendage (LAA) ligation

Eligibility Criteria:
Inclusion Criteria:

* Persistent symptomatic AF with failure of at least 1 anti-arrhythmic drug
* Prior pulmonary vein isolation (PVI)
* CHA2DS2VASC \> 0
* Able to tolerate and compliant with oral anticoagulation with either Warfarin, dabigatran, rivoraxaban or apixiban

Exclusion Criteria:

* Inability to follow-up as per protocol
* Prior valvular surgery or valve replacement
* Reversible cause for atrial fibrillation
* Currently on dialysis or renal replacement therapy
* Need for concomitant cardiac surgery
* History of MI or stroke ≤2 months prior to ablation
* Intolerance to oral anticoagulants
* Thrombus in the Left atrial appendage
Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece

A prospective multi-centre, non-interventional observational study, that will be conducted in several centers in Greece for a 2-year time period (completion date December 2020), to describe patient characteristics, medical history, and the clinical benefit of mepolizumab in patients with severe eosinophilic asthma newly initiated to the drug.


Eligibility Criteria:
Inclusion Criteria:

* Patients with uncontrolled severe eosinophilic asthma placed under treatment with mepolizumab, i.e. in patients with peripheral blood eosinophils ≥300 cells/μL at any measurement in the previous year or ≥150 cells/μL in a recent measurement, with poor symptom control and increased number of exacerbations (2 or more) despite optimal treatment with high doses of inhaled corticosteroids and β2 stimulants

Exclusion Criteria:

* Patient refusal to participate in the study